Lead Sponsor

Angelica Lindén Hirschberg

Age

18 - 35 years

Sex

FEMALE

Healthy Volunteers

No

•1. Autoimmune premature ovarian insufficiency defined as presence of autoantibodies against 21-OH, SCC, 17-OH and/or NALP5 or other relevant autoantibodies
•2. 18-35 yrs of age
•3. Body mass index 19-30.
•4. In fertile females, willingness to comply with effective contraceptive methods.
•5. Ability to provide informed consent

•1. Documented hypersensitivity or intolerance to rituximab
•2. Active, severe infection
•3. Severe immunosuppression
•4. Severe cardiac disease
•5. Cancer
•6. Benign tumours of the hypothalamus, pituitary, or ovary; ovarian enlargement or ovarian cyst
•7. Vaginal bleeding of unknown aetiology
•8. Hormone replacement therapy (HRT) within four weeks prior study entry.
•9. Pregnant or lactating women
•10. Concurrent treatment with other immunosuppressive drugs
•11. Vaccination within 4 weeks of infusion of study medication
•12. Severe psychiatric disorder
•13. Patient with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with Rituximab.